Clinical Trial Search

Primary: Global Aesthetic Improvement Scale — 0.95; 1.05 score on a scale

Primary: Change From Pre-Presentation to Post-Presentation in Treatment Seeking Evaluation - Intention to Seek Cognitive Behavioral Therapy — 3.23; 3.02; 3.67; 3.79 score on a…

Primary: Disease Progression as Assessed by the ALSFRS-R Total Score — -0.99; -1.00 points per month

Primary: Part 1 - Number of Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 1; 3; 3 Events

Primary: Infant Intake (mL) During the Observed Feeding — 116.7; 119.5; 107.5; 114.9 mL — p=0.76

Primary: Late Radiation Toxicities at 2 Years From the Start of Radiation Treatment — 0 Participants

Primary: Participants With Complete Absence of Ocular Pain at Day 8 — 39; 39; 0; 1 Participants

Primary: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 — 34.4; 1.0 meters — p=<0.001

Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803

Primary: Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 — 6.1; 29.1; 33.4 Percentage…

Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance

Primary: Progression-free Survival (PFS) — 23.2; 11.5 months — p==0.012

Primary: Incidence of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 5; 6 Participants

Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change